X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
azd6140 (132) 132
clopidogrel (105) 105
humans (86) 86
ticagrelor (82) 82
index medicus (81) 81
adenosine - analogs & derivatives (75) 75
safety (54) 54
acute coronary syndromes (48) 48
pharmacology & pharmacy (45) 45
male (43) 43
aspirin (40) 40
cardiac & cardiovascular systems (39) 39
female (37) 37
middle aged (36) 36
prasugrel (36) 36
p2y receptor antagonist (35) 35
inhibition (34) 34
ticlopidine - analogs & derivatives (32) 32
adenosine - adverse effects (31) 31
receptor antagonist (31) 31
adenosine - administration & dosage (30) 30
antagonist (30) 30
pharmacokinetics (30) 30
platelet aggregation inhibitors - adverse effects (30) 30
p2y (29) 29
adenosine (26) 26
adenosine - therapeutic use (26) 26
antiplatelet therapy (26) 26
treatment outcome (26) 26
adenosine - pharmacokinetics (25) 25
acute coronary syndrome (23) 23
adenosine - pharmacology (23) 23
aged (23) 23
pharmacodynamics (23) 23
platelet aggregation inhibitors - therapeutic use (23) 23
acute coronary syndrome - drug therapy (22) 22
cangrelor (21) 21
platelet aggregation inhibitors - administration & dosage (21) 21
platelets (20) 20
abridged index medicus (19) 19
adult (19) 19
drug therapy (19) 19
platelet aggregation - drug effects (19) 19
dose-response relationship, drug (18) 18
purinergic p2y receptor antagonists - adverse effects (18) 18
double-blind method (17) 17
hematology (17) 17
outcomes (17) 17
percutaneous coronary intervention (17) 17
platelet-aggregation (17) 17
purinergic p2 receptor antagonists (17) 17
tolerability (17) 17
coronary heart disease (16) 16
heart attacks (16) 16
platelet inhibition (16) 16
purinergic p2y receptor antagonists - pharmacokinetics (16) 16
thrombosis (16) 16
ticlopidine - administration & dosage (16) 16
animals (15) 15
peripheral vascular disease (15) 15
platelet aggregation inhibitors - pharmacokinetics (15) 15
platelet aggregation inhibitors - pharmacology (15) 15
purinergic p2y receptor antagonists - administration & dosage (15) 15
purinergic p2y receptor antagonists - therapeutic use (15) 15
receptors, purinergic p2y12 (14) 14
ticlopidine - therapeutic use (14) 14
administration, oral (13) 13
aggregation (13) 13
blood platelets (13) 13
dosage and administration (13) 13
dyspnea (13) 13
trial (13) 13
blood platelets - drug effects (12) 12
myocardial-infarction (12) 12
purinergic p2y receptor antagonists - pharmacology (12) 12
therapy (12) 12
ticlopidine - adverse effects (12) 12
cardiac patients (11) 11
cardiovascular disease (11) 11
care and treatment (11) 11
coronary artery disease (11) 11
double-blind (11) 11
platelet aggregation (11) 11
research (11) 11
analysis (10) 10
follow-up studies (10) 10
time factors (10) 10
aspirin - therapeutic use (9) 9
medical and health sciences (9) 9
medicin och hälsovetenskap (9) 9
medicine, general & internal (9) 9
pharmacology (9) 9
young adult (9) 9
adp (8) 8
cardiovascular (8) 8
drug therapy, combination (8) 8
p2y antagonist (8) 8
p2y receptor (8) 8
pharmacology/toxicology (8) 8
plato (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 03/2008, Volume 28, Issue 3, pp. s33 - s38
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 09/2009, Volume 7, Issue 9, pp. 1556 - 1565
Background: P2Y12 plays an important role in regulating platelet aggregation and function. This receptor is the primary target of thienopyridine antiplatelet... 
AZD6140 | P2Y12 | AZ11931285 | ticagrelor | ADP | 2MeS‐ADP | platelet aggregation | 2MeS-ADP | Platelet aggregation | Ticagrelor
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 1, pp. 35 - 43
Journal Article
Journal Article
Journal of Molecular Structure, ISSN 0022-2860, 10/2018, Volume 1170, pp. 38 - 43
N1N2 bond in molecules containing 1, 2, 3-triazoles framework is weakened and readily cleaved when N1 is attached to a strong electron-withdrawing group.... 
Ticagrelor | Triazole | Isomerization | BENZOTRIAZOLES | AZD6140 | ANTAGONIST | CHEMISTRY, PHYSICAL | IDENTIFICATION | IMPURITIES | HPLC | Drugstores | Pyrimidines | Triazoles | Pharmacy | Analysis
Journal Article
Journal of Heterocyclic Chemistry, ISSN 0022-152X, 01/2017, Volume 54, Issue 1, pp. 436 - 449
A series of novel 6‐alkylamino(alkoxyl)‐2‐propylthio‐8‐azapurine nucleosides were synthesized by an improved route, and the human antiplatelet aggregation... 
CHEMISTRY, ORGANIC | AZD6140 | THERAPY | INHIBITORS | ANALOGS | RECEPTOR ANTAGONIST | Nucleosides | Analysis
Journal Article
Thrombosis Research, ISSN 0049-3848, 2009, Volume 124, Issue 5, pp. 565 - 571
Abstract Ticagrelor (AZD6140), the first reversibly binding oral P2Y12 receptor antagonist, blocks adenosine diphosphate (ADP)-induced platelet aggregation via... 
Hematology, Oncology and Palliative Medicine | AZD6140 | Platelet aggregation | Thienopyridine | Ticagrelor | P2Y | Bleeding
Journal Article
Circulation, ISSN 0009-7322, 11/2010, Volume 122, Issue 21, pp. 2131 - 2141
Background-Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting. Ticagrelor, a reversible... 
acute coronary syndrome | thrombosis | platelets | myocardial infarction | hemorrhage | 2007 FOCUSED UPDATE | AZD6140 | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | MYOCARDIAL-INFARCTION | EFFICACY | RATIONALE | P2Y RECEPTOR ANTAGONIST | ASPIRIN | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | ASSOCIATION | Purinergic P2Y Receptor Antagonists - administration & dosage | Coronary Thrombosis - epidemiology | Humans | Middle Aged | Male | Angioplasty, Balloon, Coronary | Purinergic P2Y Receptor Antagonists - adverse effects | Adenosine - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Coronary Thrombosis - prevention & control | Ticlopidine - adverse effects | Electrocardiography | Ticlopidine - administration & dosage | Female | Platelet Aggregation Inhibitors - adverse effects | Acute Coronary Syndrome - epidemiology | Hemorrhage - epidemiology | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Adenosine - administration & dosage | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Acute Coronary Syndrome - diagnosis | Aged | Hemorrhage - chemically induced | Usage | Angioplasty | Patient outcomes | Clopidogrel | Drug therapy | Ticagrelor | Health aspects | Heart attack | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 01/2019, Volume 555, pp. 11 - 18
[Display omitted] The aim of this study is to improve the bioavailability of ticagrelor, BCS class 4 drug, using solid dispersion technique, and to evaluate... 
Neusilin® US2 | Solid dispersion | d-α-Tocopheryl polyethylene glycol-1000 succinate | Ticagrelor | Pharmacokinetics | Caco-2 cell | d-alpha-Tocopheryl polyethylene glycol-1000 | AZD6140 | ANTAGONIST | BERBERINE | VITAMIN-E TPGS | P-GLYCOPROTEIN | CLOPIDOGREL | INHIBITION | DISSOLUTION | PHARMACOLOGY & PHARMACY | ABSORPTION | POWDER | succinate Neusilin (R) US2
Journal Article
European Heart Journal, ISSN 0195-668X, 12/2011, Volume 32, Issue 23, pp. 2945 - 2953
Journal Article
Korean Circulation Journal, ISSN 1738-5520, 09/2017, Volume 47, Issue 5, pp. 689 - 691
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2016, Volume 67, Issue 10, pp. 1145 - 1154
Journal Article
AMERICAN HEART JOURNAL, ISSN 0002-8703, 04/2009, Volume 157, Issue 4, pp. 599 - 605
Journal Article